Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait
复制标题
DOI：
10.2217/imt-2021-0026
复制
发表时间：
2021-04-06
期刊：
影响因子：
2.8
通讯作者：
Brandi, Giovanni
中科院分区：
文献类型：
--
作者：
Rizzo, Alessandro;Ricci, Angela Dalia;Brandi, Giovanni
晚期肝细胞癌（HCC）患者预后差。然而，近年来，在这种情况下出现了几种新的治疗方法，其中免疫检查点抑制剂的作用已被研究。其中，PD-L1抑制剂atezolizumab联合贝伐珠单抗在不可切除疾病的初治患者中报告了前所未有的结果，最近发表的IMbrave 150 III期试验显示了该组合优于索拉非尼单药治疗，并且在经历了十多年的“停滞”之后，HCC医学界有了新的护理标准。在此，我们研究了atezolizumab在晚期HCC中的发展和影响，总结了其作用机制、药代动力学和I期至III期临床试验的最新证据。
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However, recent years have seen the advent of several novel treatments in this setting, where the role of immune checkpoint inhibitors has been investigated. Among these, the PD-L1 inhibitor atezolizumab in combination with bevacizumab has reported unprecedented results in treatment-naive patients with unresectable disease, with the recently published IMbrave150 Phase III trial showing the superiority of the combination over sorafenib monotherapy, and after having attended more than a decade of 'stagnation', the HCC medical community has a new standard of care. Herein, we examine the development and the impact of atezolizumab in advanced HCC, summarizing the mechanism of action, pharmacokinetics and recent evidence from Phase I to III clinical trials.